The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCL
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, shares the findings from a subgroup analysis of the Phase I/II BRUIN study (NCT03740529), investigating pirtobrutinib in patients with mantle cell lymphoma (MCL) previously treated with a covalent BTK inhibitor. In this updated two-year analysis, patients with high-risk MCL, such as blastoid or pleomorphic variants, achieved responses consistent with the rest of the cohort, while responses differed in two other subgroups. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
